Evidence map›Paper›PMID 40474131›Full record

ArticleBMC cancer2025

A radiogenomics study on

Xuanyi Li, Weijun Shi, Qianwen Zhang, Xinhui Lin, Hongzan Sun

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Molecular Imaging in Photon Radiotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuanyi LiDepartment of Radiology, Shengjing Hospital of China Medical University, Sanhao Street No. 36, Heping District, Shenyang, 110004, China.
Weijun ShiThe Second Clinical College of China Medical University, Shenyang, 110004, China.
Qianwen ZhangThe Second Clinical College of China Medical University, Shenyang, 110004, China.
Xinhui LinSchool of Stomatology, China Medical University, Shenyang, Liaoning, 110004, China.
Hongzan SunDepartment of Radiology, Shengjing Hospital of China Medical University, Sanhao Street No. 36, Heping District, Shenyang, 110004, China. sunhongzan@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo create an automated PET/CT segmentation method and radiomics model to forecast Mismatch repair (MMR) and TP53 gene expression in endometrial cancer patients, and to examine the effect of gene expression variability on image texture features. MATERIALS AND

methodsWe generated two datasets in this retrospective and exploratory study. The first, with 123 histopathologically confirmed patient cases, was used to develop an endometrial cancer segmentation model. The second dataset, including 249 patients for MMR and 179 for TP53 mutation prediction, was derived from PET/CT exams and immunohistochemical analysis. A PET-based Attention-U Net network was used for segmentation, followed by region-growing with co-registered PET and CT images. Feature models were constructed using PET, CT, and combined data, with model selection based on performance comparison.

resultsOur segmentation model achieved 99.99% training accuracy and a dice coefficient of 97.35%, with validation accuracy at 99.93% and a dice coefficient of 84.81%. The combined PET + CT model demonstrated superior predictive power for both genes, with AUCs of 0.8146 and 0.8102 for MMR, and 0.8833 and 0.8150 for TP53 in training and test sets, respectively. MMR-related protein heterogeneity and TP53 expression differences were predominantly seen in PET images.

conclusionAn efficient deep learning algorithm for endometrial cancer segmentation has been established, highlighting the enhanced predictive power of integrated PET and CT radiomics for MMR and TP53 expression. The study underscores the distinct influences of MMR and TP53 gene expression on tumor characteristics.

Indexed as

Deep LearningEndometrial NeoplasmsPositron Emission Tomography Computed TomographyAgedAlgorithmsDNA Mismatch RepairFemaleFluorodeoxyglucose F18GenomicsHumansMiddle AgedMutationRadiopharmaceuticalsRetrospective StudiesTumor Suppressor Protein p53Fluorodeoxyglucose F18RadiopharmaceuticalsTP53 protein, humanTumor Suppressor Protein p5318F-FDG PET/CTEndometrial cancerMMRRadiogenomicsTP53

Identifiers

PMID40474131
PMCPMC12142843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.